Narrowly defined case | Non-narrowly defined case | ||
---|---|---|---|
(n = 201) | (n = 303) | ||
Age(years) | Median [IQR] | 72 (60–81) | 70 (57–79.5) |
<40 yr | 18 (9.0) | 29 (9.6) | |
≧40 yr. <60 yr | 31 (15.4) | 57 (18.8) | |
≧60 yr. <80 yr | 95 (47.3) | 141 (46.5) | |
≧80 yr | 57 (28.4) | 76 (25.1) | |
Male | 102 (50.7) | 153 (50.5) | |
Predisposing disease | Primary AI | 7 (3.5) | 16 (5.3) |
Central AI | 75 (37.3) | 61 (20.1) | |
Others | 119 (59.2) | 226 (74.6) | |
Indication for hospital admissiona | Adrenal insufficiencyb | 52 (25.9) | 30 (9.9) |
Pituitary disease | 41 (20.4) | 33 (10.9) | |
Cancer | 7 (3.5) | 67 (22.1) | |
Infection | 15 (7.5) | 41 (13.5) | |
Cardiovascular disease | 7 (3.5) | 14 (4.6) | |
Sepsis | 6 (3.0) | 11 (3.6) | |
Adrenal tumor | 4 (2.0) | 6 (2.0) | |
AI-related clinical symptomc | 40 (19.9) | 18 (5.9) | |
Therapeutic GC regimen | HC | 149 (74.1) | 179 (59.1) |
mPSL | 24 (11.9) | 50 (16.5) | |
DEX | 15 (7.5) | 29 (9.6) | |
Others | 13 (6.5) | 45 (14.9) | |
Hormone testing | ACTH | 178 (88.6) | 56 (18.5) |
Cortisol | 194 (96.5) | 64 (21.1) | |
Endocrine stimulation testd | 27 (13.4) | 13 (4.3) | |
Adrenal cortex stimulation test | 15 (7.5) | 6 (2.0) | |
Visited before admission | Yes, within 90 days before | 124 (61.7) | 213 (70.3) |
Yes, within 14 days before | 90 (44.8) | 151 (49.8) | |
Under GC-related medication | Oral GC | 33 (16.4) | 71 (23.4) |
HC equivalent daily dosage (mg) | 20 (12–30) | 20 (20–40) | |
Median [IQR] | |||
Intranasal GC | 0 (0.0) | 0 (0.0) | |
Inhaled GC | 8 (4.0) | 7 (2.3) | |
Drug interacting with GC | 4 (2.0) | 9 (3.0) |